Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

María González-Cao,Clara Mayo-de-las-Casas,Juana Oramas,Miguel Angel Berciano Guerrero,Luis De la Cruz,Pablo Cerezuela-Fuentes,Ana Arance,Eva Muñoz-Couselo,Enrique Espinosa,Teresa Puertolas,Robert Diaz Beveridge,Sebastian Ochenduszko,Maria Jose Villanueva Silva,Laura Basterretxea,L. Bellido,Delvys Rodriguez Abreu,Ana Drozdowskyj,Miguel Angel Molina-Vila,Jose A. Lopez-Martin,Alfonso Berrocal

Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

2021

9528Background: Combination of vemurafenib plus cobimetinib is approved for the treatment of BRAF-mutated advanced melanoma. Although patients initially respond to treatment, resistance emerges bef...

Keywords:

Schedule
Oncology
advanced melanoma
Medicine
Internal medicine
Randomized controlled trial
Vemurafenib
Cobimetinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations